Alicia Morgans, MD: Nuclear medicine specialists play a big role in particular as we talk about radiopharmaceuticals and radioligand therapies. Jeremie, can you talk about your role as a nuclear ...
Patients with metastatic castration-resistant prostate cancer treated with radioligand therapy, a form of targeted therapy, had improvements in PSA levels and survival with favorable side effect ...
Vancouver, British Columbia, Canada — Current guidelines used to plan salvage radiation treatments in patients with local recurrence of prostate cancer should be updated to take into consideration ...
IN the fight against prostate cancer, one biomarker is proving to be a game changer. According to Sunway Medical Centre Clinical Head and Nuclear Medicine Physician Associate Professor Dr Tan Teik Hin ...
There are currently several different FDA approved radiopharmaceuticals being used in both large academic and small practice settings to accurately stage and identify local and metastatic prostate ...
TREATMENT. >> A DOCTOR HERE SAYS HE IS THE FIRST IN THE STATEO T PROVIDE A SPECIAL THERAPY THAT GIVES HOPE TO MEN FIGHTING PROSTATE CANCER. DOCTOR ASHOK MUTHUKRISHNAN HAS WORKED TO BRING PSMA THERAPY ...
lab assistant_TS_506712196 PSMA expression on circulating tumor cells in men with mCRPC increases upon disease progression despite treatment with novel antiandrogens. Prostate-specific membrane ...
The researchers also assessed a prognostic biomarker, fluorodeoxyglucose (FDG) PET. A high volume of disease on FDG-PET (metabolic tumor volume [MTV] > 200 mL) was associated with a worse prognosis ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback